Significance of p53 and Bcl-2 Protein Expression in Human Breast Ductal Carcinoma

Davidoff A.M. , Herndon JE II , Glover N.S. . Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery. 1991; 110: 259–264.

Thor A.D. , Moore DH II , Edgerton S.M. . Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992; 84: 845–855.

Rosanelli G.P. , Steindorfer P. , Wirnsberger G.H. . Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters. Anticancer Res. 1995; 15: 581–586.

Borg A. , Lennerstrand J. , Stenmark-Askmalm M. . Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer. 1995; 71: 1013–1017.

Tsuda H. , Hirohashi S. . Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer. 1994; 57: 498–503.

Faille A. , De Cremoux P. , Extra J.M. . p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 1994; 69: 1145–1150.

Isola J. , Visakorpi T. , Holli K. . Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992; 84: 1109–1114.

Molina R. , Segui M.A. , Climent M.A. . p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res. 1998; 18: 507–511.

Falette N. , Paperin M.P. , Treilleux I. . Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 1998; 58: 1451–1455.

Martinazzi M. , Crivelli F. , Zampatti C. . Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol. 1993; 100: 213–217.

Marchetti A. , Buttitta F. , Pellegrini S. . p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 1993; 53: 4665–4669.

Gee J.M. , Robertson J.F. , Ellis I.O. . Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 1994; 59: 619–628.

Nathan B. , Gusterson B. , Jadayel D. . Expression of Bcl-2 in primary breast cancer and its correlation with tumor phenotype. Ann Oncol. 1994; 5: 409–414.

Bargou R.C. , Daniel P.T. , Mapara M.Y. . Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 1995; 60: 854–859.

Leek R.D. , Kaklamanis L. , Pezzella F. . Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer. 1994; 69: 135–139.

Silvestrini R. , Veneroni S. , Daidone M.G. . The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994; 86: 499–504.

Haldar S. , Negrini M. , Monne M. . Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54: 2095–2097.

Kastan M.B. , Onyekwere O. , Sidransky D. . Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51: 6304–6311.

Zambetti G.P. , Bargonetti J. , Walker K. . Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 1992; 6: 1143–1152.

Kern S.E. , Pietenpol J.A. , Thiagalingam S. . Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992; 256: 827–830.

Fields S. , Jang S.K. . Presence of a potent transcription activating sequence in the p53 protein. Science. 1990; 249: 1046–1049.

Thorlacius S. , Jonasdottir O. , Eyfjord J.E. . Loss of heterozygosity at selective sites on chromosomes 13 and 17 in human breast carcinoma. Anticancer Res. 1991; 11: 1501–1507.

Varley J.M. , Brammar W.J. , Lane D.P. . Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene. 1991; 6: 413–421.

Andersen T.I. , Holm R. , Nesland J.M. . Prognostic significance of TP53 alterations in breast carcinomas. Br J Cancer. 1993; 68: 540–548.

Gasparini G. , Weidner N. , Bevilacqua P. . Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994; 12: 454–466.

Berns E.M. , van Staveren I.L. , Look M.P. . Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 1998; 77: 1130–1136.

Bosari S. , Lee A.K. , Viale G. . Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchow Arch A Pathol Anat Histopathol. 1992; 421: 291–295.

Walker R.A. , Dearing S.J. , Lane D.P. . Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol. 1991; 165: 203–211.

Yonish-Rouach E. , Resnitzky D. , Lotem J. . Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991; 352: 345–347.

Shaw P. , Bovey R. , Tardy S. . Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A. 1992; 89: 4495–4499.

Vaux D.L. , Cory S. , Adams J.M. . bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988; 335: 440–442.

Hockenbery D. , Nunez G. , Milliman C. . Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990; 348: 334–336.

Nunez G. , London L. , Hockenbery D. . Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol. 1990; 144: 3602–3610.

Bukholm I.K. , Nesland J.M. , Karesen R. . Interaction between Bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53. Int J Cancer. 1997; 73: 38–41.

Poller D.N. , Hutchings C.E. , Galea M. . p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB2 protein over-expression, and oestrogen receptor. Br J Cancer. 1992; 66: 583–588.

Poller D.N. , Roberts E.C. , Bell J.A. . p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB2 protein. Hum Pathol. 1993; 24: 463–468.

Ferrieres G. , Cuny M. , Simony-Lafontaine J. . Variation of Bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. J Pathol. 1997; 183: 204–211.